Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Akeso Approved to Launch Dual Checkpoint Inhibitor for Cervical Cancer

publication date: Jun 29, 2022

Hangzhou Akeso announced its PD-1/CTLA-4 bi-specific antibody was approved to launch in China as a second line therapy for relapsed or metastatic cervical cancer (R/M CC) patients who progressed after platinum-based chemotherapy. Globally, cadonilimab injection is first dual immune checkpoint inhibitor bi-specific antibody approved for commercialization. Akeso is continuing to conduct multiple trials of cadonilimab as a first-line therapy for cervical cancer and in solid tumor cancer indications. More details....

Stock Symbol: (HK: 9926)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Beijing and Digital
November 8-11, 2022
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022